Alnylam Pharmaceuticals, Inc. (ALNY) — Fair Value Analysis

Base-case fair value (P50): $340.35 · Current price: $300.97 · Verdict: Fairly Valued

The Verdict on ALNY

Our latest Monte Carlo simulations indicate Alnylam Pharmaceuticals Inc (ALNY) is currently Fairly Valued. While the stock trades at $300.97, our median fair value (P50) stands at $340.35, suggesting a modest +13.1% upside potential. This narrow differential places ALNY squarely in the "Fairly Valued" category, implying that its current market price accurately reflects the company's intrinsic value based on thousands of forward-looking financial scenarios. Investors seeking significant near-term discounts or premiums might find this valuation balanced, aligning with a prudent investment outlook given its current financial and operational profile.

How ALNY stacks up against peers

Alnylam Pharmaceuticals Inc. (ALNY) maintains an average quality tier, indicating its operational and financial health metrics are broadly aligned with its sector peers. This assessment, derived from a rigorous comparison within its industry, suggests that ALNY's fundamental standing neither significantly elevates its fair value nor introduces unusual downside risks compared to others in its space. The average quality tier reinforces the Monte Carlo simulations' finding of a fair valuation, as it does not present compelling reasons for ALNY to trade at a substantial premium or discount relative to its current operations and financial health.

What this means for investors

For investors considering Alnylam Pharmaceuticals Inc. (ALNY), the "Fairly Valued" verdict, coupled with an average quality tier, suggests a balanced risk-reward profile at the current $300.97. The Monte Carlo simulations, which project a median fair value of $340.35 and an +13.1% upside, indicate that the market is largely efficient in pricing ALNY today. While there are always potential upside or downside scenarios, the current analysis points to a stock that isn't significantly mispriced. For a comprehensive view, leverage FairCurve to see the full bear and bull case distribution and track ALNY's fair value as new fundamentals are released.